Table 6 Characteristics of patients after PSM

Sex

Male

199 (59.9%)

97 (58.4%)

102 (61.4%)

0.575

Female

133 (40.1%)

69 (41.6%)

64 (38.6%)

Age (years)

≤55

58 (17.4%)

30 (18.1%)

28 (16.9%)

0.879

56–60

42 (12.7%)

20 (12.0%)

22 (13.2%)

61–65

65 (19.6%)

32 (19.3%)

33 (19.9%)

66–70

74 (22.3%)

34 (20.5%)

40 (24.1%)

> 70

93 (28.0%)

50 (30.1%)

43 (25.9%)

Location

Rectum

171 (51.5%)

88 (53.0%)

83 (50.0%)

0.583

Colon

161 (48.5%)

78 (47.0%)

83 (50.0%)

Size (cm)

≤5.0

183 (55.1%)

92 (55.4%)

91 (54.8%)

0.833

> 5.0

143 (44.0%)

72 (43.4%)

74 (44.6%)

Unknown

3 (0.9%)

2 (1.2%)

1 (0.6%)

Differentiation

Well-moderate

309 (93.1%)

154 (92.8%)

155 (93.4%)

0.829

Poor

23 (6.9%)

12 (7.2%)

11 (6.6%)

T category

3

127 (38.3%)

62 (37.3%)

65 (39.2%)

0.735

4

205 (61.7%)

104 (62.7%)

101 (60.8%)

CEA^b (ng/mL)

< 5

175 (52.7%)

88 (53.0%)

87 (52.4%)

0.968

≥5

118 (35.5%)

58 (34.9%)

60 (36.1%)

Unknown

39 (11.8%)

20 (12.1%)

19 (11.5%)

Examined lymph nodes

< 12

84 (25.3%)

41 (24.7%)

43 (25.9%)

0.801

≥12

248 (74.7%)

125 (75.3%)

123 (74.1%)

Vessel carcinoma embolus

Negative

320 (96.4%)

160 (96.4%)

160 (96.4%)

1.000

Positive

12 (3.6%)

6 (3.6%)

6 (3.6%)

CCVD^c

Negative

287 (86.4%)

147 (88.6%)

140 (84.3%)

0.262

Positive

45 (13.6%)

19 (11.4%)

26 (15.7%)

PLR^d

≤130

176 (53.0%)

85 (51.2%)

91 (54.8%)

0.509

> 130

156 (47.0%)

81 (48.8%)

75 (45.2%)